Immuno-oncology (IO) has fundamentally reshaped cancer treatment, with immune checkpoint inhibitors, cellular therapies, and combination immunotherapy strategies now integrated across multiple malignancies. As the field continues to evolve, there is a growing need for physicians and researchers trained not only in clinical oncology but also in tumor immunology, biomarker development, and translational research.
Immuno-oncology fellowships are typically embedded within hematology-oncology training programs or offered as specialized research tracks. These programs combine clinical exposure, laboratory-based investigation, and early-phase clinical trial involvement, preparing trainees to contribute to both patient care and therapeutic innovation.
Core Elements of Immuno-Oncology Training
Leading programs in immuno-oncology generally provide structured exposure to:
- Checkpoint inhibitor therapy across solid tumors and hematologic malignancies
- Immune-related adverse event (irAE) management, including multidisciplinary care models
- Biomarker development, including PD-L1, tumor mutational burden (TMB), and emerging genomic and immune signatures
- Translational immunology, including tumor microenvironment analysis and immune escape mechanisms
- Early-phase clinical trials, particularly phase I/II immunotherapy and combination strategies
These components reflect the increasingly integrated nature of modern oncology practice.
Leading Global Immuno-Oncology Fellowship Programs
As immuno-oncology continues to evolve, specialized training environments that integrate clinical trials, translational research, and immunobiology are becoming increasingly important. Several global centers offer structured fellowship pathways designed to train the next generation of physician-scientists in this rapidly advancing field.
National Cancer Institute (NCI), USA
The National Cancer Institute (NCI) provides one of the most comprehensive immuno-oncology training ecosystems through its Center for Cancer Research (CCR) in Bethesda.
The program is uniquely positioned within a federally funded, intramural research model, enabling direct access to:
- Investigator-initiated and first-in-human trials, including early-phase immunotherapies
- Advanced platforms in cellular therapy, including TCR-engineered and CAR-T approaches
- Research in tumor immunology, immunogenomics, and resistance mechanisms
Trainees are embedded in highly translational programs spanning:
- Adoptive cell therapy
- Neoantigen discovery and vaccine development
- Checkpoint inhibitor biology and combination strategies
The NCI environment is particularly well suited for those pursuing physician-scientist careers, offering protected research time, interdisciplinary collaboration, and exposure to cutting-edge immunotherapy development.
University College London Hospitals (UCLH), United Kingdom
University College London Hospitals (UCLH), in partnership with the Cancer Research UK (CRUK) network, offers a robust academic and clinical framework for immuno-oncology training.
The program provides:
- Access to early-phase clinical trials, including novel checkpoint inhibitors and combination regimens
- Integration with biomarker-driven research programs, particularly in tumor immune profiling
Training pathways include:
- Clinical oncology fellowships
- Academic tracks leading to PhD or MD(Res) degrees
Research areas emphasize:
- Tumor microenvironment characterization
- Immune profiling and biomarker development
- Precision immunotherapy strategies
UCLH is particularly strong in bridging clinical trial participation with laboratory-based translational research, making it an ideal setting for trainees interested in biomarker-driven oncology.
Institut Gustave Roussy (IGR), France
Institut Gustave Roussy (IGR) is one of Europe’s largest and most influential cancer centers and a major hub for experimental therapeutics and early-phase immuno-oncology trials.
The institute is internationally recognized for:
- Conducting first-in-human and phase I trials of novel immunotherapies
- Development of bispecific antibodies, checkpoint inhibitors, and immune modulators
Fellowship training focuses on:
- Early drug development and clinical trial design
- Translational research and biomarker integration
- Pharmacodynamics and resistance mechanisms
IGR offers a highly structured environment for clinicians aiming to specialize in phase I oncology and drug development, with strong collaboration between clinical investigators and laboratory scientists.
National University Cancer Institute Singapore (NCIS), Singapore
The National University Cancer Institute Singapore (NCIS) represents a leading immuno-oncology center in Asia, with a strong emphasis on regional cancer biology and global clinical research integration.
The institute:
- Participates in multinational clinical trials in immunotherapy
- Develops population-specific approaches to cancer treatment, reflecting genetic and epidemiologic diversity in Asia
Training programs combine:
- Clinical oncology exposure
- Translational and laboratory research
- Health systems and implementation science
Key research areas include:
- Tumor immunology in Asian populations
- Biomarker development and validation
- Real-world implementation of immunotherapy strategies
NCIS offers a unique perspective on how immunotherapy is adapted across diverse patient populations, making it particularly valuable for those interested in global oncology.
Emerging Directions in Immuno-Oncology Training
As immuno-oncology evolves, training programs are increasingly incorporating:
- Combination immunotherapy strategies (checkpoint inhibitors + targeted therapy, chemotherapy, or radiation)
- Next-generation immune targets (LAG-3, TIGIT, bispecific antibodies)
- Cellular therapies beyond CAR-T, including tumor-infiltrating lymphocytes (TILs)
- AI-driven biomarker discovery and treatment selection
These developments highlight the need for training programs that bridge clinical oncology with advanced immunologic and computational approaches.
Conclusion
Immuno-oncology fellowships at leading global institutions provide a comprehensive platform for training in both clinical and translational cancer immunotherapy. These programs equip physicians and researchers with the skills required to manage complex immunotherapy treatments, interpret emerging biomarkers, and contribute to the development of next-generation therapeutic strategies.
As the field continues to expand, structured training in immuno-oncology will remain essential for advancing precision cancer care and improving patient outcomes worldwide.
You Can Watch More on OncoDaily Youtube TV